Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2020-12-21 10:00:14
Oslo, Norway, 21 December 2020
Nordic Nanovector ASA (OSE: NANOV) provides an update for its Financial Calendar
for 2021.
18 February 2021 - Quarterly Report - Q4'2020 / FY'2020
15 April 2021 - Annual General Meeting
26 May 2021 - Quarterly Report - Q1'2021
27 August 2021 - Quarterly Report - Q2'2021 / 1H'2021
18 November 2021 - Quarterly Report - Q3'2021
The dates are subject to change. The time and location of the presentations will
be announced in due time.
This information is published pursuant to the requirements set out in the
Continuing obligations.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to
Betalutin[®] and intends to actively participate in the commercialisation of
Betalutin[®] in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.